Safety of serial monthly administration of triple-dose gadopentetate dimeglumine in multiple sclerosis patients: preliminary results of the BECOME trial.
Wolansky
Leo J
LJ
Haghighi
Mohammad H
MH
Sevdalis
Evangelia
E
Cook
Stuart D
SD
Sethi
Nilay
N
Liu
Jiang
J
Joseph
George
G
Tulloch
Kimberly
K
Cadavid
Diego
D
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D003287:Contrast Media / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D019786:Gadolinium DTPA / Q000008:administration & dosage* / Q000009:adverse effects; D000068717:Glatiramer Acetate; D006801:Humans; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000473:pathology*; D010455:Peptides / Q000627:therapeutic use; D012449:Safety
D000276:Adjuvants, Immunologic; D003287:Contrast Media; D010455:Peptides; D000068576:Interferon beta-1b; D000068717:Glatiramer Acetate; D016899:Interferon-beta; D019786:Gadolinium DTPA